BGM vs Zhengye Biotechnology
BGM and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGM and ZYBT compare
BGM grew revenue faster over the last twelve months (51.1% versus −37.6% for Zhengye Biotechnology).
BGM keeps more of each dollar of sales as profit, with a net margin of −52.6% compared with −60.0% at Zhengye Biotechnology.
BGM scores higher on the StockData Score (9 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGM | ZYBT |
|---|---|---|
| Size and price | ||
| Share price | $8.13 | $1.52 |
| Change, 1 year | −97.1% | −30.9% |
| Change, 5 years | −98.3% | – |
| Beta (5Y) | 1.92 | 0.32 |
| Employees | 206 | 51 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 51.1% (better) | −37.6% |
| Revenue growth, 5Y average | −5.4% | – |
| Net income growth (TTM) | – | −717% |
| Profitability | ||
| Gross margin | 16.6% | 20.5% (better) |
| Operating margin | −33.2% (better) | −60.6% |
| Net margin | −52.6% (better) | −60.0% |
| FCF margin | −10.4% | 10.6% (better) |
| Return on equity | −9.2% (better) | −26.1% |
| Return on invested capital | −4.8% (better) | −18.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.26 (better) |
| Interest coverage | – | −20.7× |
| Current ratio | 1.24 (better) | 1.14 |
| Piotroski F-score | 4 (better) | 3 |
| Ownership | ||
| Held by institutions | 0.00% | – |
| Held by insiders | 52.5% | 90.7% |
| Short interest, % of float | 0.00% | – |
Go deeper
- BGM stock overview
- BGM income statement
- BGM valuation and score
- ZYBT stock overview
- ZYBT income statement
- ZYBT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.